Products

What will AGI do for Becaplermin?

This classification denotes a platelet-derived growth factor with the molecular formula C532H892N162O153S9, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1B56C968OA, more generally known as becaplermin. European Medicines Agency schedules becaplermin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00680MIG. The term BECAPLERMIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 10, no. 3, 1996, list 36. BECAPLERMIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule Becaplermin under HS 29371900 and SITC 54154. SMILES:. As of Q4 2014, BECAPLERMIN remains the US FDA Preferred Term for this commodity. . Becaplermin bears US NLM identifiers UMLS ID C0379135 and NCI Concept Code C1668.

How AGI delivers it

Four ways AGI delivers for Becaplermin

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Becaplermin, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Becaplermin, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Becaplermin connects

measured by

  • Assay Puritymodel
  • Bacterial Endotoxin Contentmodel
  • Bioactivity Potencymodel
  • Enzyme Specific Activitymodel
  • Host-Cell Protein Contentmodel
  • Protein Puritymodel